Prosetta Biosciences, based in San Francisco, is a biotechnology company focused on creating innovative therapeutics for a range of diseases. The company specializes in identifying and advancing novel small molecules that modulate the assembly of multi-protein complexes within cells. This unique approach to drug discovery aims to restore molecular homeostasis by working in tandem with the body's own regulatory mechanisms, offering a new strategy distinct from most drugs available today.

Prosetta operates in the biotechnology and pharmaceutical markets, serving clients that include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development (R&D) of therapeutic compounds, which are then licensed to pharmaceutical companies or developed in-house for clinical trials. Revenue is generated through licensing agreements, milestone payments, and royalties from successfully commercialized drugs.

The company's oncology programs have identified two compounds with anti-proliferative properties effective against approximately 75 different cancers. In the antiviral respiratory space, Prosetta has discovered that viruses share a common, energy-dependent capsid assembly process, leading to the development of antiviral compounds targeting this mechanism across various viral families.

Keywords: biotechnology, therapeutics, multi-protein complexes, drug discovery, oncology, antiviral, small molecules, molecular homeostasis, R&D, licensing.